All In Biotech

Drug Trial Radar · NCT02320032

An Open-Label Study of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia

A Phase 1, Randomized, Open-Label Study Evaluating the Pharmacokinetics of Various Dosing Regimens of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia

Last checked: Nov 20, 2026Latest source record: Aug 29, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 140 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

140

Actual

Start

Dec 2014

Primary completion

Apr 2016

Study completion Apr 2016

Sponsor

Lead sponsor
Alkermes, Inc.Industry
Sponsor type
Industry
First posted
Dec 19, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of various doses and dosing intervals of aripiprazole lauroxil.

Conditions

  • Schizophrenia

Interventions

  • Aripiprazole LauroxilDrug

    Gluteal IM injection, given once every 4 to 8 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. AUC 0-lastTime frame: Up to 45 weeks
  2. C maxTime frame: Up to 45 weeks
  3. T maxTime frame: Up to 45 weeks

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • Alkermes Investigational Site

    Little Rock, Arkansas

  • Alkermes Investigational Site

    Cerritos, California

  • Alkermes Investigational Site

    Garden Grove, California

  • Alkermes Investigational Site

    Washington D.C., District of Columbia

  • Alkermes Investigational Site

    Lauderhill, Florida

  • Alkermes Investigational Site

    Leesburg, Florida

  • Alkermes Investigational Site

    Maitland, Florida

  • Alkermes Investigational Site

    Oakland Park, Florida

  • Alkermes Investigational Site

    Tampa, Florida

  • Alkermes Investigational Site

    Atlanta, Georgia

  • Alkermes Investigational Site

    Chicago, Illinois

  • Alkermes Investigational Site

    Hoffman Estates, Illinois

  • Alkermes Investigational Site

    St Louis, Missouri

  • Alkermes Investigational Site

    Marlton, New Jersey

  • Alkermes Investigational Site

    Austin, Texas

  • Alkermes Investigational Site

    Dallas, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.